Search
Crotalus adamanteus antivenin
go.drugbank.com/drugs/DB13893ApprovedThe majority of people bitten are males and about 50% occur in the age group of 18 to 28 [F116]. … Crotalus adamanteus antivenin is derived and purified immunoglobulin fragments obtained from other domestic animals such as sheep previously immunized with Crotalus adamanteus (Eastern Diamondback rattlesnake
Aprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigationalApproximately 10-15% of patients with hypertension have resistant hypertension, defined as uncontrolled high blood pressure despite the combined use of a renin-angiotensin system blocker, a calcium channel … blocker, and a diuretic at maximally tolerated doses.
Categories: Cytochrome P-450 CYP2C18 Inhibitors, Cytochrome P-450 CYP3A InducersMolnupiravir
go.drugbank.com/drugs/DB15661Investigational[A193029] Recent studies have shown molnupiravir inhibits replication of human and bat coronaviruses, including SARS-CoV-2, in mice and human airway epithelial cells. … Molnupiravir (EIDD-2801, MK-4482) is the isopropylester prodrug of [N4-hydroxycytidine].
Pumactant
go.drugbank.com/drugs/DB04955ExperimentalIt is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG). … Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates.
Ripretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigationalRipretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020. … [L13769] It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.[L13778]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsSNS-314
go.drugbank.com/drugs/DB06134InvestigationalSNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. … SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours.
Salts: SNS-314 mesylateSynonyms: 1-(3-chlorophenyl)-3-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}ureaElafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigationalElafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist [A263833] that works to inhibit bile acid synthesis. … [L50768] On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersFlibanserin
go.drugbank.com/drugs/DB04908ApprovedInvestigationalwell as an effect on increasing norepinephrine and dopamine neurotransmitters. … It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBempedoic acid
go.drugbank.com/drugs/DB11936ApprovedInvestigational[L12153] About 1 in 4 patients, or 15 million Americans with elevated LDL-C, are insufficiently managed with maximally tolerated statin therapy alone, requiring additional treatment for hypercholesterolemia … High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events.
Rilonacept
go.drugbank.com/drugs/DB06372ApprovedInvestigationalRilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) … Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1.